Day: July 9, 2021

Series  RIKB 24 0415Settlement Date  07/14/2021Total Amount Allocated (MM)  5,470All Bids Awarded At (Price / Yield)  99.339 / 2.750Total Number of Bids Received  16Total Amount of All Bids Received (MM)  5,970Total Number of Successful Bids  12Number of Bids Allocated in Full  12Lowest Price / Highest Yield Allocated  99.339 / 2.750Highest Price / Lowest Yield Allocated  99.455 / 2.710Lowest Price / Highest Yield Allocated in Full  99.339 / 2.750Weighted Average of Successful Bids (Price/Yield)  99.389 / 2.730Best Bid (Price / Yield)  99.455 / 2.710Worst Bid (Price / Yield)  99.310 / 2.760Weighted Average of All Bids Received (Price / Yield)  99.383 / 2.730Percentage Partial Allocation (Approximate)  100.00 %Bid to Cover Ratio  1.09

Subjects will be exposed under controlled clinical facilities and medical monitoring to A/Perth/16/2009 (H3N2) or human rhinovirus (hRV-16) to gauge Ampligen’s effectiveness against those, and potentially other viruses OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza. This antiviral study will be conducted by hVIVO, a subsidiary of Open Orphan plc, a rapidly growing specialist pharmaceutical services clinical research organization and world leader in vaccine and antiviral testing using human challenge clinical trials. The trial is expected to commence in Q4...

Real-World Claims Data Presented at Annual European Association of Urology Congress Reveal Overall Complication Rates are Lowest after Treatment with the UroLift System WAYNE, Pa., July 09, 2021 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE:TFX) today announced that the largest U.S. healthcare claims and utilization analysis for benign prostatic hyperplasia (BPH) surgical and minimally invasive procedures reveals that overall complication rates are lowest after treatment with the UroLift® System. The research study titled “Analysis of Real-World Healthcare Data of Outcomes of Interventional Procedures in BPH”, which was sponsored by Teleflex, was presented by Dr. Steven Kaplan of Mount Sinai today at the 36th Annual European Association of Urology (EAU) Congress. Dr. Daniel Rukstalis+ of Prisma USC Division of Urology was a co-author...

MORF-057 well tolerated across all phase 1 cohorts Dose-dependent α4β7 receptor occupancy (RO) observed with receptor saturation at 100 mg dose Biomarker changes including lymphocyte subset migration and CCR9 transcript levels provide early proof of biology Conference call today at 8:00 AM ET WALTHAM, Mass., July 09, 2021 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced positive results from its full phase 1 clinical trial for MORF-057, an oral small molecule inhibitor of the α4β7 integrin in development for the treatment of inflammatory bowel disease (IBD). The data were shared today in an ePoster presentation at the Congress of European Crohn’s and Colitis Organisation (ECCO)...

PRESS RELEASE  July 9, 2021  HALF-YEARLY ACHIEVEMENT REPORT ON KERING SHAREQUOTATIONS LIQUIDITY MANDATE AND SIGNING OF A CONTRACT AMENDMENT CHANGING THE RESOURCES ALLOCATED TO THE LIQUIDITY ACCOUNT Pursuant to the liquidity mandate granted by Kering to Rothschild Martin Maurel on February 13, 2019, the following assets appeared on the liquidity account as of June 30, 2021:•        0 Share•        €50,212,359.00  As a reminder, the following assets appeared on the liquidity account as of December 31, 2020:•        0 Share•        €50,187,988.00 In addition, Kering and Rothschild Martin Maurel signed an amendment to the liquidity contract that came into effect on July 1st, 2021. This amendment provides a reduction of €25 million in the resources allocated to the liquidity account. Therefore, on July 1st, the following assets appeared...

Monthly declaration of the total number of shares and voting rights composing the company’s capital (at June 30th, 2021)    This declaration is established in accordance with Article L.233-8 II of the French Code de Commerce and of Article 223-11 of the Règlement Général of the Autorité des marchés financiers (AMF). Date: June 30th, 2021 Total number of shares composing the capital: 37,646,645 Total number of voting rights, gross (1): 37,871,452 Total number of voting rights, net (2): 37,848,955         (1) In accordance with the second paragraph of article 223-11 of the Règlement Général of the AMF, the gross total of voting rights is based on the total number of shares composing the company’s capital which have voting rights, including shares deprived of their voting rights (2) The net total of voting rights is equal to the gross...

Reference is made to the stock exchange announcements by SeaBird Exploration PLC (in the process of changing its name to Green Energy Group, hereinafter referred to as the “Company“) on 30 June and 1 July 2021 regarding the successful completion of a private placement (the “Private Placement“), and a potential subsequent offering (the “Subsequent Offering“) of up to 1,750,000 new shares directed towards shareholders of the Company as of 30 June 2021 who were not allocated shares in the Private Placement. Since the completion of the Private Placement, the Company’s shares have over time traded on the Oslo Stock Exchange, with significant trading volume, at prices below the subscription price in the Private Placement of NOK 4.50 per share. Accordingly, shareholders wishing to neutralize the dilutive...

Half-year liquidity contract statement for JCDecaux S.A. Paris, July 8th, 2021 – Under the liquidity contract entered into between JCDecaux S.A. (Euronext Paris: DEC), the number one outdoor advertising company worldwide, and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th, 2021:34,908 shares €4,371,849.35 Number of executions on buy side on semester: 1,392 Number of executions on sell side on semester: 1,519 Traded volume on buy side on semester: 507,413 shares for €10,217,645.20 Traded volume on sell side on semester: 547,505 shares for €11,132,225.53As a reminder:the following resources appeared on the last half year statement on December 31st, 2020 on the liquidity account:75,000 shares €3,467,761.46 Number of executions on buy side on semester: 1,494 Number of executions on sell side...